-
Andrew M. Chan, PhD - cancer cell signaling and developing mouse models of human gliomas.
-
Veronica H. Flood, MD - coagulation defects and von Willebrand disease.
-
Jill Gershan, PhD - development of cell-based vaccine for the treatment of breast cancer and breast cancer stem cells.
-
Joan C. Gill, MD - molecular and clinical biology of von Willebrand disease, coumadin pharmacogenetics in children, immunology of inhibitor formation in hemophilia, T-cell responses to hepatitis C synthetic peptides in HCV-infected hemophilic patients, replacement therapy in hemophilia.
-
Sandra L. Haberichter, PhD - cell biology and molecular mechanisms of von Willebrand disease.
-
Cheryl A. Hillery, MD - mechanisms of vaso-occlusion and vascular dysfunction in human and murine sickle cell disease, including roles of inflammation, coagulation pathways, hemolysis and oxidative injury. Effect of co-morbid asthma in murine and human sickle cell disease. Nociceptive mechanisms underlying sickle cell pain.
-
Bryon Johnson, PhD - bone marrow transplantation, immune memory, immune therapy for cancer, pediatric malignancies, neuroblastoma, tumor vaccines.
-
Robert R. Montgomery, MD - molecular and clinical biology of VWD, gene therapy of hemophilia.
-
Qizhen Shi, MD, PhD - hemophilia, the association between VWF and FVIII, gene therapy, immune response in hemophilia gene therapy.
-
Fritz Sieber, PhD - development of novel anti-cancer agents, prevention, and mitigation of damage to normal tissue in patients undergoing radiation therapy.
-
Nancy Wandersee, PhD - red blood cell membrane/membrane skeleton; hereditary spherocytosis and elliptocytosis; sickle cell disease; hemolysis and vascular injury;mouse models; pathophysiology of stroke, thrombosis, and vascular dysfunction